IP Library › Granted Patent US 9,675,671
Granted Patent B2
US 9,675,671 · App. 14/594,980 · Granted Jun 13, 2017

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof

Inventor: Hugh McTavish (Pine Springs, MN)
Assignee: IGF Oncology, LLC
A61K38/191A61K31/196A61K31/4184A61K31/519A61K47/48269A61K51/08C07K14/485C07K14/495C07K14/52C07K14/525C07K14/65A61K38/00C07K2319/02C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,675,671
App. No.
14/594,980
Granted
Jun 13, 2017
Kind
B2
Abstract

Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.

Claims (11)

1. A fusion protein comprising either SEQ ID NO:1 or residues 2-18 of SEQ ID NO:1; fused directly to the N-terminus of a cytokine.

2. The fusion protein of claim 1 wherein the cytokine is a ligand to ErbB-1 or IGFR1.

3. The fusion protein of claim 1 wherein the cytokine is tumor necrosis factor-alpha.

4. The fusion protein of claim 3 comprising SEQ ID NO: 17 or residues 2-175 of SEQ ID NO: 17.

5. The fusion protein of claim 1 wherein the cytokine is selected from a group consisting of: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, residues 2-54 of SEQ ID NO:9, residues 40-89 of SEQ ID NO:10, residues 101-184 of SEQ ID NO:11, residues 63-148 of SEQ ID NO:12, and residues 32-111 of SEQ ID NO:13.

6. The fusion protein of claim 5 wherein the cytokine is SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.

7. The fusion protein of claim 5 wherein the cytokine is residues 2-54 of SEQ ID NO:9, residues 40-89 of SEQ ID NO:10, residues 101-184 of SEQ ID NO:11, residues 63-148 of SEQ ID NO:12, or residues 32-111 of SEQ ID NO:13.

8. The fusion protein of claim 5 wherein the fusion protein comprises SEQ ID NO:2 or residues 2-88 of SEQ ID NO:2.

9. The fusion protein of claim 5 wherein the cytokine is residues 2-54 of SEQ ID NO:9.

10. A fusion protein consisting of either SEQ ID NO:1 or residues 2-18 of SEQ ID NO:1 fused to the N terminus of a cytokine selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, residues 2-54 of SEQ ID NO:9, residues 40-89 of SEQ ID NO:10, residues 101-184 of SEQ ID NO:11, residues 63-148 of SEQ ID NO:12, or residues 32-111 of SEQ ID NO:13.

11. The fusion protein of claim 10 consisting of SEQ ID NO:2 or residues 2-88 of SEQ ID NO:2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2016
From: MCTAVISH, HUGH
To: IGF ONCOLOGY, LLC
Reel/Frame 039935/0203 →
Continuity (2)
Provisional Application 61926386 · Jan 12, 2014
Related Publication 20150196656A1 · Jul 16, 2015